rs,
CEO of Eugia Pharma Specialties Limited, and Dr. Satakarni Makkapati - CEO of Aurobindo’s biosimilars, Vaccines and Peptides businesses. We will begin the call with summary highlights from the manageme
5,809 crore
be discussing ex-Natrol numbers throughout the call. For Q4, the company registered a revenue of 5,809 crores with the decrease of 3.2% quarter-on-quarter. The EBITDA before FOREX and other income declined b
3.2%
throughout the call. For Q4, the company registered a revenue of 5,809 crores with the decrease of 3.2% quarter-on-quarter. The EBITDA before FOREX and other income declined by 23.6% year on year and de
23.6%
with the decrease of 3.2% quarter-on-quarter. The EBITDA before FOREX and other income declined by 23.6% year on year and declined by 4% quarter-on- quarter to ₹974.74 crores. EBITDA margin for the quarte
4%
n-quarter. The EBITDA before FOREX and other income declined by 23.6% year on year and declined by 4% quarter-on- quarter to ₹974.74 crores. EBITDA margin for the quarter was 16.8% and for the year FY2
₹974.74 crore
re FOREX and other income declined by 23.6% year on year and declined by 4% quarter-on- quarter to ₹974.74 crores. EBITDA margin for the quarter was 16.8% and for the year FY22 was at 18.7%, however, EBITDA marg
16.8%
on year and declined by 4% quarter-on- quarter to ₹974.74 crores. EBITDA margin for the quarter was 16.8% and for the year FY22 was at 18.7%, however, EBITDA margin before R&D is 24.2% for the quarter aga
18.7%
n- quarter to ₹974.74 crores. EBITDA margin for the quarter was 16.8% and for the year FY22 was at 18.7%, however, EBITDA margin before R&D is 24.2% for the quarter against 23.5% of last quarter. Net pro
24.2%
for the quarter was 16.8% and for the year FY22 was at 18.7%, however, EBITDA margin before R&D is 24.2% for the quarter against 23.5% of last quarter. Net profit decreased by 28.1% year on year and 4.7%
23.5%
for the year FY22 was at 18.7%, however, EBITDA margin before R&D is 24.2% for the quarter against 23.5% of last quarter. Net profit decreased by 28.1% year on year and 4.7% quarter-on-quarter to ₹576 C
28.1%
margin before R&D is 24.2% for the quarter against 23.5% of last quarter. Net profit decreased by 28.1% year on year and 4.7% quarter-on-quarter to ₹576 Crores. In terms of the business breakdown formul
4.7%
4.2% for the quarter against 23.5% of last quarter. Net profit decreased by 28.1% year on year and 4.7% quarter-on-quarter to ₹576 Crores. In terms of the business breakdown formulation business in Q4 F